Abstract:Gastrointestinal stromal tumours (GISTs) are soft-tissue sarcomas of the gastrointestinal tract. Surgery is the standard treatment for localised disease, but the risk of relapse and progression to more advanced disease is substantial. Following the discovery of the molecular mechanisms underlying GISTs, targeted therapies for advanced GIST were developed, with the first being the tyrosine kinase inhibitor (TKI) imatinib. Imatinib is recommended in international guidelines as first-line therapy to reduce the risk of GIST relapse in high-risk patients, and for locally advanced, inoperable and metastatic disease. Unfortunately, imatinib resistance frequently occurs and, therefore, second-line (sunitinib) and third-line (regorafenib) TKIs have been developed. Treatment options are limited for patients with GIST that has progressed despite these therapies. A number of other TKIs for advanced/metastatic GIST have been approved in some countries. Ripretinib is approved as fourth-line treatment of GIST and avapritinib is approved for GIST harbouring specific genetic mutations, while larotrectinib and entrectinib are approved for solid tumours (including GIST) with specific genetic mutations. In Japan, pimitespib, a heat shock protein 90 (HSP90) inhibitor, is now available as a fourth-line therapy for GIST. Clinical studies of pimitespib have indicated that it has good efficacy and tolerability, importantly not displaying the ocular toxicity of previously developed HSP90 inhibitors. Additional approaches for advanced GIST have been investigated, including alternative uses of currently available TKIs (such as combination therapy), novel TKIs, antibody-drug conjugates, and immunotherapies. Given the poor prognosis of advanced GIST, the development of new therapies remains an important goal.

[Diagnosis and Treatment for Complicated Gastrointestinal Stromal Tumors].

[Strategies in Diagnosis and Management for Advanced or Metastatic Gastrointestinal Stromal Tumor].

Role of surgery in treatment of recurrent or metastatic gastrointestinal stromal tumor

[Efficacy of Tyrosine Kinase Inhibitor Therapy Combined with Surgical Resection in Patients with Metastatic Gastrointestinal Stromal Tumor].

[Challenges of Gastrointestinal Stromal Tumor in the Era of Targeted Therapy].

Progress in Diagnosis and Treatment of Gastrointestinal Stromal Tumors

Treatment of patients with postoperative recurrent-metastatic gastrointestinal stromal tumor

[Treatment Progress of Gastrointestinal Stromal Tumor].

Advances of endoscopic and surgical management in gastrointestinal stromal tumors

[Treatment of Recurrent or Metastatic Gastrointestinal Stromal Tumor: Surgery or Not].

The Diagnosis and Treatment of Colorectal Gastrointestinal Stromal Tumors

Treatment Strategies for Recurrent or Metastatic Gastrointestinal Stromal Tumor

Standard treatment for liver metastases with gastrointestinal stromal tumors

Clinical diagnosis and treatment of gastrointestinal stromal tumors:A report of 47 cases

Treatment Strategy for Recurrent and Metastatic Gastrointestinal Stromal Tumors

Colorectal Gastrointestinal Stromal Tumors (gists): A Retrospective Study of Reported Cases

Current status of and future prospects for the treatment of unresectable or metastatic gastrointestinal stromal tumours

Diagnosis, Treatment and Prognostic Anlysis on 136 Cases of Gastrointestinal Stromal Tumors

Systemic Therapy for Gastrointestinal Stromal Tumor: Current Standards and Emerging Challenges

[Surgical Treatment for Gastrointestinal Stromal Tumor].

[Lancet in the Era of Targeted Drug Therapy: the Role of Surgery in the Management of Advanced Gastrointestinal Stromal Tumor].